FDA Permits Juul E-Cigarette Sales, Citing Benefits Outweighing Risks
The FDA has authorized Juul to continue selling its e-cigarettes, including tobacco and menthol flavors, reversing a previous ban. Regulators determined that the benefits for adult smokers outweigh potential health risks.
NBC NewsJuul can continue to sell e-cigarettes, FDA says
PBS NewsHourJuul can continue selling e-cigarettes as FDA says vaping benefits outweigh risks
Washington ExaminerFDA reauthorizes Juul e-cigarettes following federal ban
ABC NewsJuul can continue selling its tobacco and menthol e-cigarettes, FDA says
Overview
The FDA has permitted Juul to continue selling its e-cigarettes, including tobacco and menthol products, in the U.S. market.
This decision reverses an initial June 2022 order by the FDA that required Juul to remove its products from the market.
FDA regulators determined that the benefits of Juul's e-cigarettes for adult smokers outweigh the potential health risks, based on various studies.
Juul is now one of only two U.S. companies authorized by the FDA to sell menthol-flavored vapes, highlighting its market position.
Despite past scrutiny over alleged marketing to young consumers and initial regulatory concerns, Juul's products can continue to be sold.
Analysis
Center-leaning sources frame the FDA's decision on Juul by consistently emphasizing the company's controversial history and its widely perceived role in sparking the teen vaping trend. The narrative highlights past lawsuits, public opposition, and the negative societal impact of Juul's products, contextualizing the regulatory approval within a broader story of public health concerns and corporate accountability.